Braveheart Bio, Inc. (BRVE) Kâr Dağıtımı

Braveheart Bio, Inc. is a US-based company operating in industry. The company is headquartered in San Francisco, California and currently employs 30 full-time employees. The company went IPO on 2026-08-06. Braveheart Bio, Inc. is a clinical stage biopharmaceutical company. The firm is focused on developing therapies for patients with hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases. Its lead product candidate, BHB 1893, is an oral small-molecule cardiac myosin inhibitor (CMI), that it is developing for the treatment of obstructive HCM (oHCM) and non-obstructive HCM (nHCM). Its pipeline is focused on advancing BHB-1893 across multiple cardiovascular indications with significant unmet need. HCM is a chronic, progressive disease characterized by abnormal thickening and impaired relaxation of the heart.